**Name:** **Francine M. Foss, M.D**

**Appointment:** Professor of Medicine, Section of Hematology and Bone Marrow Transplantation

Professor of Dermatology (secondary appointment)

**School:** Yale University School of Medicine, New Haven CT 06510

**Education: Education:**

AB Dartmouth College, Hanover, New Hampshire (Biochemistry) 1978

MD University of Massachusetts Medical School, Worcester, MA 1982

1982-83 Intern- Internal Medicine, Brigham and Women’s Hospital, Boston, Massachusetts

1983-85 Residency- Internal Medicine Brigham and Women’s Hospital, Boston, Massachusetts

1985-88 Medical Oncology Fellowship, Medicine Branch, National Cancer Institute, National

Institutes of Health, Bethesda, Maryland

1988-92 Assistant Professor, Department of Medicine, Uniformed Services University for the Health Sciences, Bethesda, Maryland

1988-92 Senior Investigator, NCI-Navy Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

1988-92 Chairman and Principal Investigator Cutaneous T-Cell Lymphoma Program National Cancer Institute, National Institutes of Health

1992-97 Associate Professor, Sections of Hematology-Oncology and Bio-molecular Medicine, Boston University Medical Center, Boston, Massachusetts

1998-05 Associate Professor, Department of Medicine Hematology/Oncology) Director, Lymphoma and Experimental Therapeutics, Tufts New England Medical Center, Boston, Massachusetts

2005- Professor, Department of Medicine, Yale University School of Medicine

2005- Professor, Department of Dermatology, Yale University School of Medicine

**Administrative Positions:**

2005-present Assistant Director, Clinical Investigations, Hematologic Malignancies, Yale University School of Medicine

2005-2010 Program Leader, Immunobiology and Immunotherapy Program, Yale Comprehensive Cancer Center

2005-present Director, Cutaneous Lymphoma Program, Yale University School of Medicine

2016 Director of Lymphoma , Yale University School of Medicine

**Board Certification:**

Diplomat, National Board of Medical Examiners, 1983  
Commonwealth of Massachusetts, 1984

Diplomat, American Board of Internal Medicine, 1985

Diplomat, American Board of Internal Medicine, Medical Oncology, 1987

State of Connecticut, 2005

**Professional Honors and Recognition:**

**International/ National/Regional**

2007 Ethyl F. Donaghue Foundation Grant

2005 Pink Magazine- Top 9 Women in Cancer Research

2004 George Santos Award, American Society of Bone Marrow Transplantation

2000 Member, Society for Biological Therapy

2000 Member, American Society of Bone Marrow Transplantation

2000 Member, New York Academy of Science

1994 Member, American Society of Hematology

1990 Member, American Association for Cancer Research

1988 Member, American Society of Clinical Oncology

1987 Member, American College of Physicians

1985 Member, American Medical Association

**Professional Service:**

**Journal Services**

Editor/Associate Editor  
 1998-present Journal of Clinical Oncology (Editorial Board)

2000-present Clinical Lymphoma (Editorial Board)

2000-American Journal of Hematology- Editorial Board

2000-present Hematology

2001-present Bone Marrow Transplantation

**Leadership Positions**

International Society for Cutaneous Lymphomas- Board of Directors

United States Cutaneous Lymphoma Consortium- Board of Directors

United States Cutaneous Lymphoma Consortium- Registry Committee CoChair

International T Cell Lymphoma Project- Board of Directors

COMPLETE T Cell Lymphoma Registry Project- Founder, Director

International T Cell Forum- Founder and Co-Chair

Director, Lymphoma Research Program, Yale University School of Medicine

**Committees:**

**National** CALGB Lymphoma Core Committee

CALGB Transplant Committee

ASCO Education Committee

ASBMT/CIBMTR Immunobiology Committee

ASBMT/CIBMTR Lymphoma Committee

**University** Cancer Center Steering Committee (2005-12)

Tenure and Allotment Committee Medicine (2007-9)

Dean’s Office-Scientific Misconduct Committee

Tenure and Promotion Committee, Department of Medicine

Yale Cancer Center “Answers” Radio Show

Study Sections

National Cancer Institute, Lymphoma Spore Review Committee

National Cancer Institute, Metabolism Branch Review Committee National Cancer Institute, Laboratory of Molecular Biology

AACR Hematologic Malignancies Research Scientific Review Committee

Reviewer

1994-present American Journal Clinical Pathology (Reviewer)

1996-present Journal of Cellular Biochemistry Supplement (Reviewer)  
 1996-present Blood (Reviewer)

1997-present New England Journal of Medicine (Reviewer)

1997-present European Journal of Cancer (Reviewer)

1998-present Journal of the American Academy of Dermatology (Reviewer)

1999-present Clinical Cancer Research (Reviewer)

2000-present Cancer (Reviewer)

2000**-**presentOncology (Reviewer)

2000-present Clinical Lymphoma (Reviewer)

2000-present Biology of Blood and Marrow Transplantation (Reviewer)

2001-present Annals New York Academy Sciences (Reviewer)

2002-present Hematology American Social Hematology Education Program (Reviewer)

2002-present Bone Marrow Transplant (Reviewer)

2002-present Seminars in Oncology (Reviewer)

2002-present Current Cancer Drug Targets (Reviewer)

2003-present Leukemia Lymphoma (Reviewer)

2003-present Hematology Oncology Clinic North America (Reviewer)

2004-present Current Opinions Oncology (Reviewer)

2004-present Best Practice Research Clinical Hematology (Reviewer)

2006-present Seminars Hematology (Reviewer)

2007-present Cancer Treatment Review (Reviewer)

2010-present Clinical Advantage Hematology Oncology (Reviewer)

2010-present Drugs (Reviewer)

2011-present Expert Opinion Drug Metab. Toxicol (Reviewer)

2013-present Best Practice Research Clinical Hematology (Reviewer)

2013-present Future Oncology (Reviewer)

**Teaching Activities**

**Thesis Mentor**

Alexander Urbano, PhD ( thesis advisor) 1998

Eamon Sweeney, PhD ( committee member) 1999\

Marie France Demierre, MD (deceased)

Gullu Gorgun, PhD (thesis advisor) 2003

Larry Cosenza, PhD (committee member) 2002

Eric Lansigan, MD (Research Fellowship)

Jaehyuk Choi MD, PhD (trainee)

Neha Menghan, PharmD (thesis advisor, 2012)

Juliet Fraser Gibson MD (thesis advisor) 2014

Benoit Cyrenne, MD ( thesis advisor) 2017-

**Bibliography:**

**(1-174)**

1. **Weed J, Gibson J, Lewis J, Carlson K, Foss F, Choi J, Li P, Girardi M.** 2017. FISH Panel for Leukemic CTCL. J Invest Dermatol **137:**751-753.

2. **Perreault S, Baker J, Medoff E, Pratt K, Foss F, Isufi I, Seropian S, Cooper DL.** 2017. Infusion reactions are common after high-dose carmustine in BEAM chemotherapy and are not reduced by lengthening the time of administration. Support Care Cancer **25:**205-208.

3. **Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter PA, Savani BN.** 2017. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant doi:10.1016/j.bbmt.2017.07.027.

4. **Kaulen LD, Foss FM, Fulbright RK, Huttner A, Baehring JM.** 2017. Neurolymphomatosis of the thoracic sympathetic chain. Neurology doi:10.1212/WNL.0000000000004600.

5. **Kann BH, Park HS, Yeboa DN, Aneja S, Girardi M, Foss FM, Roberts KB, Wilson LD.** 2017. Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sezary Syndrome. Clin Lymphoma Myeloma Leuk **17:**520-526 e522.

6. **Hsi ED, Horwitz SM, Carson KR, Pinter-Brown LC, Rosen ST, Pro B, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Collie AM, Gruver AM, Grzywacz BJ, Turakhia S, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM.** 2017. Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. Clin Lymphoma Myeloma Leuk **17:**193-200.

7. **Foss FM, Girardi M.** 2017. Mycosis Fungoides and Sezary Syndrome. Hematol Oncol Clin North Am **31:**297-315.

8. **Foss F, Pro B, Miles Prince H, Sokol L, Caballero D, Horwitz S, Coiffier B.** 2017. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Med **6:**36-44.

9. **Foss F, Horwitz S, Pro B, Miles Prince H, Sokol L, Balser B, Wolfson J, Coiffier B.** 2017. Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol **10:**154.

10. **Cyrenne BM, Lewis J, Weed J, Carlson K, Mirza FN, Foss F, Girardi M.** 2017. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients. Blood doi:10.1182/blood-2017-06-792150.

11. **Carson KR, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA, Shustov AR, Advani RH, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM.** 2017. A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer **123:**1174-1183.

12. **Pro B, Horwitz SM, Prince HM, Foss FM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Iyer SP, Shustov AR, Wolfson J, Balser BE, Coiffier B.** 2016. Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. Hematol Oncol doi:10.1002/hon.2320.

13. **Nadeau M, Perreault S, Seropian S, Foss F, Isufi I, Cooper DL.** 2016. The use of basiliximab-infliximab combination for the treatment of severe gastrointestinal acute GvHD. Bone Marrow Transplant **51:**273-276.

14. **Gibson JF, Huang J, Liu KJ, Carlson KR, Foss F, Choi J, Edelson R, Hussong JW, Mohl R, Hill S, Girardi M.** 2016. Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vbeta chain restriction. J Am Acad Dermatol **74:**870-877.

15. **Foss F, Horwitz S, Pro B, Prince HM, Sokol L, Balser B, Wolfson J, Coiffier B.** 2016. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol **9:**22.

16. **Foss F, Duvic M, Lerner A, Waksman J, Whittaker S.** 2016. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. Clin Lymphoma Myeloma Leuk **16:**637-643.

17. **Cooper DL, Medoff E, Patel N, Baker J, Pratt K, Foss F, Seropian SE, Perreault S, Wu Y.** 2016. Autologous Stem Cell Mobilization in the Age of Plerixafor. Clin Lymphoma Myeloma Leuk **16:**411-416.

18. **Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, Evens AM, Foss F, Horwitz S, Pro B, Pinter-Brown LC, Smith SM, Shustov AR, Savage KJ, Vose JM.** 2016. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. Br J Haematol **172:**535-544.

19. **Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, Stadler R, Wood GS, Beylot-Barry M, Pham-Ledard A, Foss F, Girardi M, Bagot M, Michel L, Battistella M, Guitart J, Kuzel TM, Martinez-Escala ME, Estrach T, Papadavid E, Antoniou C, Rigopoulos D, Nikolaou V, Sugaya M, Miyagaki T, Gniadecki R, Sanches JA, Cury-Martins J, Miyashiro D, Servitje O, Muniesa C, Berti E, Onida F, Corti L, Hodak E, Amitay-Laish I, Ortiz-Romero PL, Rodriguez-Peralto JL, Knobler R, Porkert S, Bauer W, Pimpinelli N, Grandi V, Cowan R, Rook A, Kim E, Pileri A, Patrizi A, Pujol RM, Wong H, et al.** 2015. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol **33:**3766-3773.

20. **O'Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, Hess G, Jurczak W, Knoblauch P, Chawla S, Bhat G, Choi MR, Walewski J, Savage K, Foss F, Allen LF, Shustov A.** 2015. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. J Clin Oncol **33:**2492-2499.

21. **James E, Sokhn JG, Gibson JF, Carlson K, Subtil A, Girardi M, Wilson LD, Foss F.** 2015. CD4 + primary cutaneous small/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature. Leuk Lymphoma **56:**951-957.

22. **Iyer SP, Foss FF.** 2015. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma. Oncologist **20:**1084-1091.

23. **Horwitz S, Coiffier B, Foss F, Prince HM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Pinter-Brown L, Iyer SP, Shustov A, Nichols J, Balser J, Balser B, Pro B.** 2015. Utility of (1)(8)fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. Ann Oncol **26:**774-779.

24. **Gibson JF, Kapur L, Sokhn J, Xu M, Foss FM.** 2015. A fatal case of primary cutaneous gamma-delta T-cell lymphoma complicated by HLH and cardiac amyloidosis. Clin Case Rep **3:**34-38.

25. **Gibson JF, Alpdogan O, Subtil A, Girardi M, Wilson LD, Roberts K, Foss F.** 2015. Hematopoietic stem cell transplantation for primary cutaneous gammadelta T-cell lymphoma and refractory subcutaneous panniculitis-like T-cell lymphoma. J Am Acad Dermatol **72:**1010-1015 e1015.

26. **Frankel AE, Woo JH, Ahn C, Foss FM, Duvic M, Neville PH, Neville DM.** 2015. Resimmune, an anti-CD3epsilon recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. Haematologica **100:**794-800.

27. **Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Belt RJ, Jacobsen ED, Laurent G, Ben-Yehuda D, Beylot-Barry M, Hillen U, Knoblauch P, Bhat G, Chawla S, Allen LF, Pohlman B.** 2015. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol **168:**811-819.

28. **Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, Dwyer KM, Zhang X, Kurman MR, Ballerini R, Liu L, Kim YH.** 2015. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood **125:**1883-1889.

29. **Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, Bjornson RD, Maman Y, Wang T, Tordoff J, Carlson K, Overton JD, Liu KJ, Lewis JM, Devine L, Barbarotta L, Foss FM, Subtil A, Vonderheid EC, Edelson RL, Schatz DG, Boggon TJ, Girardi M, Lifton RP.** 2015. Genomic landscape of cutaneous T cell lymphoma. Nat Genet **47:**1011-1019.

30. **Bellei M, Nabhan C, Pesce EA, Conte L, Vose JM, Foss F, Federico M.** 2015. The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project. Curr Hematol Malig Rep **10:**448-455.

31. **Gibson JF, Foss F, Cooper D, Seropian S, Irizarry D, Barbarotta L, Lansigan F.** 2014. Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma. Br J Haematol **167:**141-144.

32. **Foss F, Coiffier B, Horwitz S, Pro B, Prince HM, Sokol L, Greenwood M, Lerner A, Caballero D, Baran E, Kim E, Nichols J, Balser B, Wolfson J, Whittaker S.** 2014. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomark Res **2:**16.

33. **Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan Iyer S, Shustov A, Nielsen T, Nichols J, Wolfson J, Balser B, Horwitz S.** 2014. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol **7:**11.

34. **Parker T, Barbarotta L, Foss F.** 2013. Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma. Future Oncol **9:**21-29.

35. **Lloyd S, Chen Z, Foss FM, Girardi M, Wilson LD.** 2013. Acute toxicity and risk of infection during total skin electron beam therapy for mycosis fungoides. J Am Acad Dermatol **69:**537-543.

36. **Foss FM, Sjak-Shie N, Goy A, Jacobsen E, Advani R, Smith MR, Komrokji R, Pendergrass K, Bolejack V.** 2013. A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. Leuk Lymphoma **54:**1373-1379.

37. **Foss FM.** 2013. Treatment strategies for peripheral T-cell lymphomas. Best Pract Res Clin Haematol **26:**43-56.

38. **Chen Y, Zheng T, Lan Q, Kim C, Qin Q, Foss F, Chen X, Holford T, Leaderer B, Boyle P, Wang C, Dai M, Liu Z, Ma S, Chanock SJ, Rothman N, Zhang Y.** 2013. Polymorphisms in DNA repair pathway genes, body mass index, and risk of non-Hodgkin lymphoma. Am J Hematol **88:**606-611.

39. **Knobler R, Duvic M, Querfeld C, Straus D, Horwitz S, Zain J, Foss F, Kuzel T, Campbell K, Geskin L.** 2012. Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. Photodermatol Photoimmunol Photomed **28:**250-257.

40. **Kim C, Zheng T, Lan Q, Chen Y, Foss F, Chen X, Holford T, Leaderer B, Boyle P, Chanock SJ, Rothman N, Zhang Y.** 2012. Genetic polymorphisms in oxidative stress pathway genes and modification of BMI and risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev **21:**866-868.

41. **Horwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, Fisher DC, Shustov AR, Bartlett NL, Delioukina ML, Koutsoukos T, Saunders ME, O'Connor OA, Duvic M.** 2012. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood **119:**4115-4122.

42. **Foss F, Horwitz SM, Coiffier B, Bartlett N, Popplewell L, Pro B, Pinter-Brown LC, Shustov A, Furman RR, Haioun C, Koutsoukos T, O'Connor OA.** 2012. Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study. Clin Lymphoma Myeloma Leuk **12:**238-243.

43. **Conti-Freitas LC, Foss-Freitas MC, Mamede RC, Foss NT.** 2012. Interferon-gamma and interleukin-10 production by mononuclear cells from patients with advanced head and neck cancer. Clinics (Sao Paulo) **67:**587-590.

44. **Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S.** 2012. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol **30:**631-636.

45. **Bi X, Zheng T, Lan Q, Xu Z, Chen Y, Zhu G, Foss F, Kim C, Dai M, Zhao P, Holford T, Leaderer B, Boyle P, Deng Q, Chanock SJ, Rothman N, Zhang Y.** 2012. Genetic polymorphisms in IL10RA and TNF modify the association between blood transfusion and risk of non-Hodgkin lymphoma. Am J Hematol **87:**766-769.

46. **Bellei M, Chiattone CS, Luminari S, Pesce EA, Cabrera ME, de Souza CA, Gabus R, Zoppegno L, Zoppegno L, Milone J, Pavlovsky A, Connors JM, Foss FM, Horwitz SM, Liang R, Montoto S, Pileri SA, Polliack A, Vose JM, Zinzani PL, Zucca E, Federico M.** 2012. T-cell lymphomas in South america and europe. Rev Bras Hematol Hemoter **34:**42-47.

47. **Aschebrook-Kilfoy B, Zheng T, Foss F, Ma S, Han X, Lan Q, Holford T, Chen Y, Leaderer B, Rothman N, Zhang Y.** 2012. Polymorphisms in immune function genes and non-Hodgkin lymphoma survival. J Cancer Surviv **6:**102-114.

48. **Querfeld C, Rosen ST, Guitart J, Rademaker A, Pezen DS, Dolan ME, Baron J, Yarosh DB, Foss F, Kuzel TM.** 2011. Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O(6)-methylguanine-DNA methyltransferase and mismatch repair proteins. Clin Cancer Res **17:**5748-5754.

49. **Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre MF, Pittelkow M, Wilson LD, Pinter-Brown L, Advani R, Parker S, Kim EJ, Junkins-Hopkins JM, Foss F, Cacchio P, Duvic M.** 2011. Sezary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol **64:**352-404.

50. **Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K.** 2011. Peripheral T-cell lymphoma. Blood **117:**6756-6767.

51. **Foss FM.** 2011. Molecular predictors of response in aggressive T-cell lymphomas. Cancer J **17:**142-148.

52. **Foss FM.** 2011. Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma. Expert Opin Drug Metab Toxicol **7:**1141-1152.

53. **Foss F, Duvic M, Olsen EA.** 2011. Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma. Am J Hematol **86:**627-630.

54. **Foss F.** 2011. Hematology: relapsed and refractory PTCL--into the therapeutic abyss. Nat Rev Clin Oncol **8:**321-322.

55. **Foss F.** 2011. Evolving Therapy of Peripheral T-cell Lymphoma: 2010 and beyond. Ther Adv Hematol **2:**161-173.

56. **Cooper DL, Pratt K, Baker J, Medoff E, Conkling-Walsh A, Foss F, Snyder E, Yen W, Seropian SE.** 2011. Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution. Clin Lymphoma Myeloma Leuk **11:**267-272.

57. **Chen Y, Zheng T, Lan Q, Foss F, Kim C, Chen X, Dai M, Li Y, Holford T, Leaderer B, Boyle P, Chanock SJ, Rothman N, Zhang Y.** 2011. Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma. Blood **117:**585-590.

58. **Shaughnessy PJ, Bolwell BJ, van Besien K, Mistrik M, Grigg A, Dodds A, Prince HM, Durrant S, Ilhan O, Parenti D, Gallo J, Foss F, Apperley J, Zhang MJ, Horowitz MM, Abhyankar S.** 2010. Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant **45:**1068-1076.

59. **Lansigan F, Stearns DM, Foss F.** 2010. Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma. Cancer Manag Res **2:**53-59.

60. **Lansigan F, Foss FM.** 2010. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs **70:**273-286.

61. **Han X, Zheng T, Foss FM, Ma S, Holford TR, Boyle P, Leaderer B, Zhao P, Dai M, Zhang Y.** 2010. Alcohol consumption and non-Hodgkin lymphoma survival. J Cancer Surviv **4:**101-109.

62. **Han X, Zheng T, Foss FM, Lan Q, Holford TR, Rothman N, Ma S, Zhang Y.** 2010. Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival. Am J Hematol **85:**51-56.

63. **Han X, Zheng T, Foss F, Holford TR, Ma S, Zhao P, Dai M, Kim C, Zhang Y, Bai Y, Zhang Y.** 2010. Vegetable and fruit intake and non-Hodgkin lymphoma survival in Connecticut women. Leuk Lymphoma **51:**1047-1054.

64. **Foss FM.** 2010. Enhancing existing approaches to peripheral T-cell lymphoma. Semin Hematol **47 Suppl 1:**S8-10.

65. **Berger C, Hoffmann K, Vasquez JG, Mane S, Lewis J, Filler R, Lin A, Zhao H, Durazzo T, Baird A, Lin W, Foss F, Christensen I, Girardi M, Tigelaar R, Edelson R.** 2010. Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy. Blood **116:**4838-4847.

66. **Armitage JO, Hsi ED, Foss FM.** 2010. Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness. Clin Adv Hematol Oncol **8:**1-15.

67. **Foss FW, Jr., Mathews TP, Kharel Y, Kennedy PC, Snyder AH, Davis MD, Lynch KR, Macdonald TL.** 2009. Synthesis and biological evaluation of sphingosine kinase substrates as sphingosine-1-phosphate receptor prodrugs. Bioorg Med Chem **17:**6123-6136.

68. **Foss FM.** 2009. The importance of accurately characterizing lymphoproliferative disease. Oncology (Williston Park) **23:**1168, 1170.

69. **Foss F, van Besien K.** 2009. Reduced-intensity and nonmyeloablative conditioning regimens. Cancer Treat Res **144:**209-232.

70. **Foss F.** 2009. Advances in the treatment of T-cell lymphomas. Clin Adv Hematol Oncol **7:**1-14; quiz 15-16.

71. **Cross JV, Rady JM, Foss FW, Lyons CE, Macdonald TL, Templeton DJ.** 2009. Nutrient isothiocyanates covalently modify and inhibit the inflammatory cytokine macrophage migration inhibitory factor (MIF). Biochem J **423:**315-321.

72. **Conti-Freitas LC, Foss-Freitas MC, Lucca LJ, da Costa JA, Mamede RC, Foss MC.** 2009. Dynamics of parathyroid hormone secretion after total parathyroidectomy and autotransplantation. World J Surg **33:**1403-1407.

73. **Zhao H, Foss FW, Jr., Breslow R.** 2008. Artificial enzymes with thiazolium and imidazolium coenzyme mimics. J Am Chem Soc **130:**12590-12591.

74. **Lansigan F, Choi J, Foss FM.** 2008. Cutaneous T-cell lymphoma. Hematol Oncol Clin North Am **22:**979-996, x.

75. **Whittaker SJ, Foss FM.** 2007. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. Cancer Treat Rev **33:**146-160.

76. **Sun Q, Zhu R, Foss FW, Jr., Macdonald TL.** 2007. Mechanisms of trovafloxacin hepatotoxicity: studies of a model cyclopropylamine-containing system. Bioorg Med Chem Lett **17:**6682-6686.

77. **Querfeld C, Rosen ST, Guitart J, Rademaker A, Foss F, Gupta R, Kuzel TM.** 2007. Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and Sezary syndrome. J Am Acad Dermatol **56:**580-583.

78. **Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M.** 2007. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol **25:**3109-3115.

79. **Kuzel TM, Li S, Eklund J, Foss F, Gascoyne R, Abramson N, Schwerkoske JF, Weller E, Horning SJ.** 2007. Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497. Leuk Lymphoma **48:**2397-2402.

80. **Hathaway T, Subtil A, Kuo P, Foss F.** 2007. Efficacy of denileukin diftitox in subcutaneous panniculitis-like T-cell lymphoma. Clin Lymphoma Myeloma **7:**541-545.

81. **Foss FW, Jr., Snyder AH, Davis MD, Rouse M, Okusa MD, Lynch KR, Macdonald TL.** 2007. Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg Med Chem **15:**663-677.

82. **Duvic M, Foss FM.** 2007. Mycosis fungoides: pathophysiology and emerging therapies. Semin Oncol **34:**S21-28.

83. **Cross JV, Foss FW, Rady JM, Macdonald TL, Templeton DJ.** 2007. The isothiocyanate class of bioactive nutrients covalently inhibit the MEKK1 protein kinase. BMC Cancer **7:**183.

84. **Choi J, Foss F.** 2007. Cutaneous T-cell lymphoma: Biologic targets for therapy. Curr Hematol Malig Rep **2:**272-277.

85. **Foss FM.** 2006. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation. Semin Hematol **43:**S35-43.

86. **Foss F, Whittaker S.** 2006. CTCL: the most common type of primary cutaneous lymphoma: introduction. Semin Oncol **33:**S1-2.

87. **Foss F.** 2006. Clinical experience with denileukin diftitox (ONTAK). Semin Oncol **33:**S11-16.

88. **Foss F.** 2006. Immunomodulatory effects of rexinoids. Semin Oncol **33:**S21-25.

89. **Duvic M, Sherman ML, Wood GS, Kuzel TM, Olsen E, Foss F, Laliberte RJ, Ryan JL, Zonno K, Rook AH.** 2006. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. J Am Acad Dermatol **55:**807-813.

90. **Dummer R, Foss F, Dreno B, Bagot M.** 2006. Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms. Semin Oncol **33:**S26-32.

91. **Choi J, Foss F.** 2006. Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia. Yale J Biol Med **79:**169-172.

92. **Chin KM, Foss FM.** 2006. Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox. Clin Lymphoma Myeloma **7:**199-204.

93. **Awad AS, Ye H, Huang L, Li L, Foss FW, Jr., Macdonald TL, Lynch KR, Okusa MD.** 2006. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol **290:**F1516-1524.

94. **Huang Z, Higgins B, Foss F.** 2005. Activity of gallium nitrate in refractory peripheral T-cell lymphoma. Clin Lymphoma **6:**43-45.

95. **Foss FM, DiVenuti GM, Chin K, Sprague K, Grodman H, Klein A, Chan G, Stiffler K, Miller KB.** 2005. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant **35:**1187-1193.

96. **Foss F, Demierre MF, DiVenuti G.** 2005. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood **106:**454-457.

97. **Miller KB, Roberts TF, Chan G, Schenkein DP, Lawrence D, Sprague K, Gorgun G, Relias V, Grodman H, Mahajan A, Foss FM.** 2004. A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease. Bone Marrow Transplant **33:**881-889.

98. **Foss FM.** 2004. Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome. Best Pract Res Clin Haematol **17:**573-584.

99. **Foss F.** 2004. Mycosis fungoides and the Sezary syndrome. Curr Opin Oncol **16:**421-428.

100. **Kuzel TM, Junghans R, Foss FM.** 2003. Novel agents for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am **17:**1459-1466, x.

101. **Foss FM, Waldmann TA.** 2003. Interleukin-2 receptor-directed therapies for cutaneous lymphomas. Hematol Oncol Clin North Am **17:**1449-1458.

102. **Foss FM, Aquino SL, Ferry JA.** 2003. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10-2003. A 72-year-old man with rapidly progressive leukemia, rash, and multiorgan failure. N Engl J Med **348:**1267-1275.

103. **Foss FM.** 2003. Extracorporeal photopheresis in the treatment of graft-vs-host disease. J Cutan Med Surg **7:**13-17.

104. **Foss F.** 2003. Overview of cutaneous T-cell lymphoma: prognostic factors and novel therapeutic approaches. Leuk Lymphoma **44 Suppl 3:**S55-61.

105. **Di Venuti G, Nawgiri R, Foss F.** 2003. Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated acute T-cell leukemia/lymphoma. Clin Lymphoma **4:**176-178.

106. **Dearden CE, Foss FM.** 2003. Peripheral T-cell lymphomas: diagnosis and management. Hematol Oncol Clin North Am **17:**1351-1366.

107. **Chan GW, Gorgun G, Miller KB, Foss FM.** 2003. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. Biol Blood Marrow Transplant **9:**170-176.

108. **Chan GW, Foss FM, Klein AK, Sprague K, Miller KB.** 2003. Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease. Biol Blood Marrow Transplant **9:**753-759.

109. **vanderSpek JC, Sutherland JA, Gill BM, Gorgun G, Foss FM, Murphy JR.** 2002. Structure function analysis of interleukin 7: requirement for an aromatic ring at position 143 of helix D. Cytokine **17:**227-233.

110. **Urbano A, Gorgun G, Foss F.** 2002. Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cells. Biochem Pharmacol **63:**689-692.

111. **Shao RH, Tian X, Gorgun G, Urbano AG, Foss FM.** 2002. Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rbeta gene. Leuk Res **26:**1077-1083.

112. **Gorgun G, van der Spek J, Cosenza L, Menevse A, Foss F.** 2002. Altered biological activity associated with C-terminal modifications of IL-7. Cytokine **20:**17-22.

113. **Gorgun G, Miller KB, Foss FM.** 2002. Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood **100:**941-947.

114. **Gorgun G, Foss F.** 2002. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood **100:**1399-1403.

115. **French LE, Alcindor T, Shapiro M, McGinnis KS, Margolis DJ, Porter D, Leonard DG, Rook AH, Foss F.** 2002. Identification of amplified clonal T cell populations in the blood of patients with chronic graft-versus-host disease: positive correlation with response to photopheresis. Bone Marrow Transplant **30:**509-515.

116. **Frankel AE, Rossi P, Kuzel TM, Foss F.** 2002. Diphtheria fusion protein therapy of chemoresistant malignancies. Curr Cancer Drug Targets **2:**19-36.

117. **Foss FM, Gorgun G, Miller KB.** 2002. Extracorporeal photopheresis in chronic graft-versus-host disease. Bone Marrow Transplant **29:**719-725.

118. **Foss FM.** 2002. Immunologic mechanisms of antitumor activity. Semin Oncol **29:**5-11.

119. **Duvic M, Kuzel TM, Olsen EA, Martin AG, Foss FM, Kim YH, Heald PW, Bacha P, Nichols J, Liepa A.** 2002. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clin Lymphoma **2:**222-228.

120. **Cosenza L, Gorgun G, Urbano A, Foss F.** 2002. Interleukin-7 receptor expression and activation in nonhaematopoietic neoplastic cell lines. Cell Signal **14:**317-325.

121. **Connors JM, Hsi ED, Foss FM.** 2002. Lymphoma of the skin. Hematology Am Soc Hematol Educ Program**:**263-282.

122. **Bailey HH, Levy D, Harris LS, Schink JC, Foss F, Beatty P, Wadler S.** 2002. A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96. Gynecol Oncol **85:**464-468.

123. **Abd-el-Baki J, Demierre MF, Li N, Foss FM.** 2002. Transformation in mycosis fungoides: the role of methotrexate. J Cutan Med Surg **6:**109-116.

124. **Rook AH, Zaki MH, Wysocka M, Wood GS, Duvic M, Showe LC, Foss F, Shapiro M, Kuzel TM, Olsen EA, Vonderheid EC, Laliberte R, Sherman ML.** 2001. The role for interleukin-12 therapy of cutaneous T cell lymphoma. Ann N Y Acad Sci **941:**177-184.

125. **Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J.** 2001. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol **19:**376-388.

126. **Kamath L, Meydani A, Foss F, Kuliopulos A.** 2001. Signaling from protease-activated receptor-1 inhibits migration and invasion of breast cancer cells. Cancer Res **61:**5933-5940.

127. **Foss FM, Bacha P, Osann KE, Demierre MF, Bell T, Kuzel T.** 2001. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma **1:**298-302.

128. **Foss FM.** 2001. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma. Ann N Y Acad Sci **941:**166-176.

129. **Argiris A, Heald P, Kuzel T, Foss FM, DiStasio S, Cooper DL, Arbuck S, Murren JR.** 2001. Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphoma. Invest New Drugs **19:**321-326.

130. **Alcindor T, Gorgun G, Miller KB, Roberts TF, Sprague K, Schenkein DP, Foss FM.** 2001. Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease. Blood **98:**1622-1625.

131. **Vose JM, Cabanillas F, O'Brien S, Dang N, Drapkin R, Foss F.** 2000. Infectious complications of pentostatin therapy. Oncology (Williston Park) **14:**41-42.

132. **Foss FM.** 2000. Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies. Semin Oncol **27:**58-63.

133. **Foss FM.** 2000. Combination therapy with purine nucleoside analogs. Oncology (Williston Park) **14:**31-35.

134. **Foss FM.** 2000. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clin Lymphoma **1:**110-116; discussion 117.

135. **Foss FM.** 2000. An oncologist's approach to therapy for cutaneous T-cell lymphoma. Clin Lymphoma **1 Suppl 1:**S9-14.

136. **Foss FM.** 2000. DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. Clin Lymphoma **1 Suppl 1:**S27-31.

137. **Foss FM, Kuzel TM.** 1999. Novel treatment approaches for cutaneous T-cell lymphoma. Cancer Treat Res **99:**227-240.

138. **Akpek G, Koh HK, Bogen S, O'Hara C, Foss FM.** 1999. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer **86:**1368-1376.

139. **Urbano A, McCaffrey R, Foss F.** 1998. Isolation and characterization of NUC70, a cytoplasmic, hematopoietic apoptotic endonuclease. J Biol Chem **273:**34820-34827.

140. **Urbano A, Koc Y, Foss FM.** 1998. Arginine butyrate downregulates p210 bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells. Leukemia **12:**930-936.

141. **Sweeney EB, Foss FM, Murphy JR, vanderSpek JC.** 1998. Interleukin 7 (IL-7) receptor-specific cell killing by DAB389 IL-7: a novel agent for the elimination of IL-7 receptor positive cells. Bioconjug Chem **9:**201-207.

142. **Saleh MN, LeMaistre CF, Kuzel TM, Foss F, Platanias LC, Schwartz G, Ratain M, Rook A, Freytes CO, Craig F, Reuben J, Sams MW, Nichols JC.** 1998. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol **39:**63-73.

143. **LeMaistre CF, Saleh MN, Kuzel TM, Foss F, Platanias LC, Schwartz G, Ratain M, Rook A, Freytes CO, Craig F, Reuben J, Nichols JC.** 1998. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood **91:**399-405.

144. **Foss FM, Saleh MN, Krueger JG, Nichols JC, Murphy JR.** 1998. Diphtheria toxin fusion proteins. Curr Top Microbiol Immunol **234:**63-81.

145. **Foss FM, Raubitscheck A, Mulshine JL, Fleisher TA, Reynolds JC, Paik CH, Neumann RD, Boland C, Perentesis P, Brown MR, Frincke JM, Lollo CP, Larson SM, Carrasquillo JA.** 1998. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clin Cancer Res **4:**2691-2700.

146. **Abd-el-Baki J, Stefanato CM, Koh HK, Demierre MF, Foss FM.** 1998. Early detection of cutaneous lymphoma. Oncology (Williston Park) **12:**1521-1530; discussion 1532-1524.

147. **Powsner RA, Zietman AL, Foss FM.** 1997. Bone marrow suppression after strontium-89 therapy and local radiation therapy in patients with diffuse marrow involvement. Clin Nucl Med **22:**147-150.

148. **Nichols J, Foss F, Kuzel TM, LeMaistre CF, Platanias L, Ratain MJ, Rook A, Saleh M, Schwartz G.** 1997. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer **33 Suppl 1:**S34-36.

149. **Demierre MF, Foss FM, Koh HK.** 1997. Proceedings of the International Consensus Conference on Cutaneous T-cell Lymphoma (CTCL) Treatment Recommendations. Boston, Massachusetts, Oct. 1 and 2, 1994. J Am Acad Dermatol **36:**460-466.

150. **Foss FA, Dickinson E, Hills M, Thomson A, Wilson V, Ebrahim S.** 1996. Missed opportunities for the prevention of cardiovascular disease among British hypertensives in primary care. Br J Gen Pract **46:**571-575.

151. **Bunn PA, Jr., Foss FM.** 1996. T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL). J Cell Biochem Suppl **24:**12-23.

152. **Bubley GJ, Xu J, Kupiec N, Sanders D, Foss F, O'Brien M, Emi Y, Teicher BA, Patierno SR.** 1996. Effect of DNA conformation on cisplatin adduct formation. Biochem Pharmacol **51:**717-721.

153. **Bogen SA, Pelley D, Charif M, McCusker M, Koh H, Foss F, Garifallou M, Arkin C, Zucker-Franklin D.** 1996. Immunophenotypic identification of Sezary cells in peripheral blood. Am J Clin Pathol **106:**739-748.

154. **Rosen ST, Foss FM.** 1995. Chemotherapy for mycosis fungoides and the Sezary syndrome. Hematol Oncol Clin North Am **9:**1109-1116.

155. **Koh HK, Jacobson JO, Foss F, Lew RA.** 1995. Is cutaneous T-cell lymphoma curable? Arch Dermatol **131:**1081-1082.

156. **Foss FM, Sausville EA.** 1995. Prognosis and staging of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am **9:**1011-1019.

157. **Foss FM, Kuzel TM.** 1995. Experimental therapies in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am **9:**1127-1137.

158. **Cheson BD, Foss FM, Phillips PH.** 1995. Clinical Trials Referral Resource: Mycosis Fungoides/Sezary Syndrome. Oncology (Williston Park) **9:**645-646.

159. **Thakur S, Lin HC, Tseng WT, Kumar S, Bravo R, Foss F, Gelinas C, Rabson AB.** 1994. Rearrangement and altered expression of the NFKB-2 gene in human cutaneous T-lymphoma cells. Oncogene **9:**2335-2344.

160. **Kuchnio M, Sausville EA, Jaffe ES, Greiner T, Foss FM, McClanahan J, Fukushima P, Stetler-Stevenson MA.** 1994. Flow cytometric detection of neoplastic T cells in patients with mycosis fungoides based on levels of T-cell receptor expression. Am J Clin Pathol **102:**856-860.

161. **Foss FM, Koc Y, Stetler-Stevenson MA, Nguyen DT, O'Brien MC, Turner R, Sausville EA.** 1994. Costimulation of cutaneous T-cell lymphoma cells by interleukin-7 and interleukin-2: potential autocrine or paracrine effectors in the Sezary syndrome. J Clin Oncol **12:**326-335.

162. **Foss FM, Ihde DC, Linnoila IR, Fischmann AB, Schechter GP, Cotelingam JD, Steinberg SM, Ghosh BC, Stocker JL, Bastian A, et al.** 1994. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. J Clin Oncol **12:**2051-2059.

163. **Foss FM, Borkowski TA, Gilliom M, Stetler-Stevenson M, Jaffe ES, Figg WD, Tompkins A, Bastian A, Nylen P, Woodworth T, et al.** 1994. Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study. Blood **84:**1765-1774.

164. **Cohen R, Jaffe ES, Stetler-Stevenson MA, Sausville EA, DeNigris EC, Woodworth T, Foss FM.** 1994. Bilateral adrenal hemorrhage and adrenal insufficiency in a patient with lymphomatous adrenal infiltration following administration of a fusion toxin (DAB486 interleukin-2). J Immunother Emphasis Tumor Immunol **16:**229-233.

165. **Cheson BD, Vena DA, Foss FM, Sorensen JM.** 1994. Neurotoxicity of purine analogs: a review. J Clin Oncol **12:**2216-2228.

166. **Graham SJ, Sharpe RW, Steinberg SM, Cotelingam JD, Sausville EA, Foss FM.** 1993. Prognostic implications of a bone marrow histopathologic classification system in mycosis fungoides and the Sezary syndrome. Cancer **72:**726-734.

167. **Cohen RB, Abdallah JM, Gray JR, Foss F.** 1993. Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Ann Intern Med **118:**114-116.

168. **Foss FM, Ihde DC, Breneman DL, Phelps RM, Fischmann AB, Schechter GP, Linnoila I, Breneman JC, Cotelingam JD, Ghosh BC, et al.** 1992. Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. J Clin Oncol **10:**1907-1913.

169. **Mickley LA, Bates SE, Richert ND, Currier S, Tanaka S, Foss F, Rosen N, Fojo AT.** 1989. Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents. J Biol Chem **264:**18031-18040.

170. **Kaye FJ, Bunn PA, Jr., Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, Glatstein EJ, Schechter GP, Phelps RM, Foss FM, et al.** 1989. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med **321:**1784-1790.

171. **Foss FM, Veillette A, Sartor O, Rosen N, Bolen JB.** 1989. Alterations in the expression of pp60c-src and p56lck associated with butyrate-induced differentiation of human colon carcinoma cells. Oncogene Res **5:**13-23.

172. **Veillette A, Foss FM, Sausville EA, Bolen JB, Rosen N.** 1987. Expression of the lck tyrosine kinase gene in human colon carcinoma and other non-lymphoid human tumor cell lines. Oncogene Res **1:**357-374.

173. **Seibel NL, Funa K, Dmitrovsky E, Foss F, Hollis GF, Kirsch IR.** 1987. Application of RNA-RNA tissue in situ hybridization in an analysis of a patient with leukemia. Hum Pathol **18:**3-8.

174. **Foss FM, Horneff J, Longo DL, Messerschmidt GL.** 1983. Cerebrospinal fluid rhinorrhea as a complication of malignant lymphoma. Am J Med **74:**1077-1079.

**Books Edited and Book Chapters**

1. Cutaneous Lymphomas. In Hematology Oncology Clinics of North America,  
   2003: WB Saunders
2. Cutaneous Lymphomas in Cancer Principles and Practice of Oncology, Devita et, 2008
3. New Frontiers in Non-Hodgkin’s Lymphoma in Clinical Malignant Hematology Sekers etal., ed, 2007
4. Cutaneous T-Cell Lymphomas in Hematology Oncology Clinics of North America, 2008
5. T Cell Lymphoproliferative Disorders, **Foss**, ed, 2012

1. **Foss, F**. Sausville E. Growth factor-dependent signal transduction: novel targets for the of treatment approaches in medical oncology. N techniques and Applications of Genome Research, K. Adolph, Ed. Academic Press, 1993, p 141-.
2. **Foss, F**. McCaffrey R. Chronic myelogenous leukemia. In Current Practice of Medicine 1996; WB Saunders
3. **Foss, F.** Cutaneous T-cell lymphoma. In Conn’s Current Therapy 1997, WB Saunders.
4. **Foss, F**. Saleh M, Krueger J, Murphy J. Diphteria toxin fusion toxins. In Clinical Appliances of Immunotoxins 1998; A. Frankel, Ed. Springer Verlag p63-82.
5. **Foss, F**. Fusion toxins. In Strategies for Immunointervention in Dermatology 1999; G. Burg Ed. Springer Verlag.
6. **Foss F**. Van Beisen. Reduced Intensity Nonmyeloablative Conditioning Regimens. In Bone Marrow Transplantation, Bishop ed. 2008
7. **Foss, F.** Extracorporeal Photopheresis. In Apheresis, Principles and Practice 2003; 2010 McLeod BC, Weinstein R, Eds.
8. **Foss, F.** Wilson L. Cutaneous T-cell Lymphomas in CANCER-Principles and Practice, 2009, Wolters Kluwer et al.
9. **Choi J, Foss F.** Photopheresis, In Apheresis, Principles and Practice, 2010.
10. **Foss, F**. Wilson L., 2011 Cutaneous T-cell Lymphomas in CANCER-Principles and Practice, Wolters Kluwer et al.
11. **Foss, F**. Systemic Involvement in Cutaneous Lymphoma. In Hall, ed, Cutaneous Lymphoma, Diagnosis and Treatment, 2011.
12. **Foss, F**. Current Therapies for T Cell Lymphoma. In Queesenbury ed, Non-Hodgkin’s Lymphoma, Models, Prognostic Factors, and Targets, Springer, 2013.
13. **Foss, F, Gibson J, et al**. 2015. Cutaneous T-cell Lymphomas in CANCER-Principles and Practice, Wolters Kluwer et al.
14. **Foss, F,** Ed. 2013. T-Cell Lymphomas. Humana Press.
15. Sokhn J, Choi **J,** Foss, F. Extracorporeal Photopheresis, in Apheresis, Principles and Practice, 2014.

**Research Support**

Targeting CXCR5 for Angioimmunoblastic T 6/1/16-5/31/18

Cell Lymphoma

NCI- R21 CA202525-01

Role: Co-PI

Effort: 10%

Chemokine Receptors for T cell Lymphoma 5/1/16-

PITCH program

Role: Co-PI

Effort: 10%

1/1/16-12/31/17

Chemokine Therapy for Mycosis Fungoides

Spatz Foundation

Role: PI

Effort: 10%

Molecular Sequencing of Sezary Syndrome

Spatz Foundation

Role: Co PI

Effort: 10%

Phase 2 Study of MK-3475 for the 5U01CA154967 09/01/14-08/01/16

Treatment of relapsed/refractory MF

NCI- CTEP

Role: P!

Effort: 5%

Prospective Longitudinal Multinational Allos Therapeutics, Inc. 11/02/2012-

Registry of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma

Role: PI

Effort: 10%

Overlap- none

**National and International Leadership**

Over the last 10 years I have been a leader in the establishment of an international T cell lymphoma working group. I initiated a T Cell Lymphoma workshop at the International Conference on Malignant Lymphoma 12 years ago and from that workshop, the United States Peripheral T cell Lymphoma group was formed. I subsequently initiated the first T Cell Lymphoma Forum, an international meeting incorporating basic and clinical sciences related to T cell lymphomas. My Co-Chairs for the meeting are Dr Kensei Tobinai from Tokyo and more recently also by Dr. Owen O’Connor from Columbia University. This year was the 8th annual meeting ([www.tcellforum.com](http://www.tcellforum.com)). This meeting is now recognized as the pre-eminent international T cell Lymphoma meeting. A number of collaborations have arisen from these meetings and there is now a world-wide effort to coordinate the care of patients with T cell lymphomas.

Another initiative that I undertook was to establish a T Cell Lymphoma Registry. I initiated and am the Principal Investigator for the COMPLETE T cell Registry (www. Clinical trials.gov/COMPLETE REGISTRY). This is a US based registry to determine the frequency of types of T cell lymphoma, physician’s treatment patterns, outcomes with therapy, and prognostic factors associated with common and rare subtypes. Thus far this registry has enrolled 500 patients in its first phase, and the second phase of enrollment is about to begin. I have also been a co-Founder of a European based registry, the TCELL PROJECT (www.TCELLPROJECT.org). This registry is similar to COMPLETE but includes pathologic review and includes many other countries in Asia, South America, and Europe as well as in the US. This registry has enrolled 1000 patients and is ongoing. In a recent initiative, I have collaborated with several countries in Latin American to initiate their own registry which will interface with our existing registries.

I was one of the founders of the United States Cutaneous Lymphoma Consortium. This organization includes oncologists, dermatologists, radiation oncologists, and pathologists and its goal is to develop novel clinical trials and to define clinical approaches for patients with cutaneous lymphomas. I also serve as a Co-Chair of the Registry Committee and have been instrumental in starting a patient registry for both T and B cell cutaneous lymphoma patients. This registry has a research focus.

**University Leadership**

I have been the Co-Director of Hematologic Malignancies and have been in charge of the clinical trial efforts in lymphoma for the last 9 years. In addition, I have been the Director of the Cutaneous Lymphoma Program. With the expansion of the lymphoma program to include three junior faculty, I have been appointed as the Director of Lymphoma. I have initiated a Lymphoma Research Collaborative seminar series and have initiated translational studies with Pharmacology and with Immunobiology. My team has received one of 12 PITCH grants awarded in the state of Connecticut for the development of novel therapeutic concepts from bench to bedside. Several grants have been submitted from our group and are pending review. My position involves mentorship of junior faculty and I am currently on 4 mentorship committees.

Over the years I have mentored a number of fellows and postdoctoral students. Dr Marie France Demierre was Director of Cutaneous Lymphoma at Boston University School of Medicine until her untimely death. Dr Erick Lansigan is now a clinical translational researcher in Lymphoma at Dartmouth Medical School, Dr Eric Winer is an Assistant Professor in Hematologic Malignancies at Brown University. Dr Larry Cosenza is the Founder and Chief Science Manager at C2 Biotechnologies, LLC. Dr Jaehyuk Choi is an Assistant Professor in Dermatology and Biochemistry and Molecular Genetics at Northwestern University School of Medicine. Dr Gullu Gorgun is now an Assistant Professor of Medicine at Oregon Health Sciences Center.

I have served on several committees within the Yale Medical School. I was a member of the Human Investigations Committee for 6 years. I served on the Dean’s Tenure Allotment Committee for three years and on the Department of Medicine Tenure and Promotions Committee for 5 years. I have also served on several ad Hoc committees.